Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

By M. Ewer, M. Vooletich, J. Durand, M. Woods, J. Davis, V. Valero, D. Lenihan. Journal of Clinical Oncology, 2005

722 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, background): “Patients who have experienced benefit with rastuzumab therapy and who have improved cardiac funcion while on a standard heart regimen may restart trastuumab therapy while on protective HF medications and lose cardiac monitoring (68).”
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. (2010, background): “The clinical outcome of patients with TIC is more favorable than that associated with cardiotoxicity from anthracyclines: cardiac function usually recovers after drug withdrawal and initiation of HF therapy.(9-12) The concept that TIC is reversible, however, remains controversial.”
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “Patients with anti-VEGF-based therapy with signs and symptoms of HF.”
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, methodology): “In contrast to anthracycline-induced cardiotoxicity, trastuzumab exposure can result in LVD and HF that appears mostly reversible.(45) At highest risk for cardiotoxicity from trastuzumab exposure are those aged >50 years, patients with underlying heart disease or hypertension, those with baseline LV”